摘要:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
The present invention is directed to novel methods of inhibiting angiogenesis using chlorotoxin agents. In some embodiments, the inventive methods include intravenous, intraocular, intravitreal, subjunctival injection, and/or topical administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment and/or amelioration of ocular diseases characterized by neovascularization, such as wet macular degeneration. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
The present invention is directed to novel methods of inhibiting angiogenesis using chlorotoxin agents. In some embodiments, the inventive methods include intravenous, intraocular, intravitreal, subjunctival injection, and/or topical administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment and/or amelioration of ocular diseases characterized by neovascularization, such as wet macular degeneration. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
The present invention is directed to methods and methods for the treatment, inhibition and/or reduction, and detection of metastatic tumors. In some embodiments, the inventive methods include systemic (e.g., intravenous) administration of a chlorotoxin agent that may or may not be labeled. In some embodiments, the inventive methods allow treatment, inhibition and/or reduction, and detection of metastases in the brain. In some embodiments, neovascularization is inhibited and/or newly formed vessels are caused to regress.
摘要:
Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
摘要:
Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
摘要:
The present invention relates to the use of a toxin moiety (e.g., a chlorotoxin moiety) as a carrier for therapeutic agents, e.g., therapeutic agents that require intracellular uptake to exert their effects. For example, in some embodiments, the present invention provides conjugates comprising a toxin (e.g., a chlorotoxin) moiety and an anti-cancer moiety and methods for using such conjugates to increase cellular uptake and/or increase specificity for cancer cells of the anti-cancer drug. In some embodiments, the present invention provides conjugates comprising a toxin moiety (e.g., a chlorotoxin moiety) and a nucleic acid agent. Also provided are methods of treatment involving administration of such conjugates, and pharmaceutical compositions and kits useful for carrying out such methods of treatment.
摘要:
A repetitive immunoassay analytical method for determination of a free analyte is carried out by loading an affinity column of covalently bound analyte with tagged antibody, passing a continuous aqueous stream of carrier liquid over the column, introducing an aliquot of a sample to be analyzed for free analyte into the carrier stream upstream of the column, and monitoring the eluting carrier stream for a signal spike resulting from the presence of tagged antibody material released from the column by the application of free analyte in the analytical sample. Many samples may be analyzed by this method before the antibody-loaded affinity column needs to be regenerated. It is also disclosed that substrate-analyte conjugates of superior stability are produced by linking a substrate to a hydroxyalkyl analyte via an amino, hydrazide, or sulfide linking group replacing a hydroxy group. Such stable substrate-analyte conjugates are useful in the production and purification of antibodies, as well as in the repetitive immunoassay of the invention.